Researchers at Mass General Brigham have discovered using sodium-glucose contratransporter 2 (SGLT2) inhibitors resulted in a decreased chance of acquiring kidney stones. The study included data from three nationwide databases of patients with type 2 diabetes who were seen in routine clinical practice.
The team analysed information from 716,406 adults with type 2 diabetes who had started taking an SGLT2 inhibitor or two other classes of diabetes medications known as GLP1 receptor agonists or dipeptidyl peptidase 4 (DPP4) inhibitors. Patients who began taking SGLT2 inhibitors had a 30 per cent lower risk of developing kidney stones than those taking GLP1 agonists and about a 25 per cent lower risk than those taking DPP4 inhibitors.
Researchers from Brigham and Women’s Hospital and Massachusetts General Hospital worked together to conduct the analysis. The findings were consistent across sex, race/ethnicity, history of chronic kidney disease and obesity.
"Our findings could help inform clinical decision-making for patients with diabetes who are at risk for developing kidney stones," said corresponding author Julie Paik, MD, ScD, MPH, of the Division of Pharmacoepidemiology and Pharmacoeconomics and the Division of Renal (Kidney) Medicine at Brigham and Women's Hospital.
